CLAIMS

1. A liquid pharmaceutical composition comprising:
   (a) an anti-IL-6 receptor (anti-IL-6R) antibody;
   (b) an histidine buffer;
   (c) a polyol;
   (d) 0.4 to 0.6 mM methionine;
   (e) a surfactant;
   (f) water for injection; and
   (g) optionally a salt;

wherein the composition has a pH between 5.5 and 7.5;
wherein the anti-IL6R antibody is selected from the group consisting of tocilizumab, sapelizumab, vobarilizumab or sarilumab.

2. The liquid pharmaceutical according to claim 1, wherein the composition has a pH between 6.0 and 6.5.

3. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the polyol is mannitol.

4. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the surfactant is a polysorbate.

5. The liquid pharmaceutical composition as claimed in claim 4, wherein the polysorbate is polysorbate 80.

6. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the optional salt is sodium chloride.

7. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the anti-IL6R antibody is tocilizumab.

8. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises:

- 15 to 200 mg/ml of the anti-IL-6R antibody;
- 10 to 25 mM histidine (or histidine buffer system);
- 190 to 210 mM mannitol;
- 0.4 to 0.6 mM methionine;
- 0.4 to 0.9 mM polysorbate 80;

- water (for injection); and
- 75 to 125 mM sodium chloride.

9. A method of manufacturing the liquid pharmaceutical composition of any one of claims 1 to 7, comprising mixing together the anti-IL-6R antibody, histidine buffer, polyol, free amino acid, and surfactant, and optionally the salt.

10. A method of manufacturing the liquid pharmaceutical composition of claim 8, comprising mixing together the anti-IL-6R antibody, histidine or histidine buffer, mannitol, methionine, polysorbate 80, and sodium chloride.

11. A kit comprising: (i) the liquid pharmaceutical composition of any one of claims 1 to 8, and (ii) a drug delivery device; wherein the liquid pharmaceutical composition is optionally contained in a separate package or container from the drug delivery device;

optionally wherein the kit further comprises a set of instructions regarding the administration of the liquid pharmaceutical composition.

12. A drug delivery device comprising a liquid pharmaceutical composition as claimed in any one of claims 1 to 8.

13. A method of manufacturing the drug delivery device of claim 12, comprising incorporating the liquid pharmaceutical composition of any one of claims 1 to 8 within a drug delivery device.

14. A liquid pharmaceutical composition as claimed in any of claims 1 to 8 for use as a medicament.

15. A liquid pharmaceutical composition as claimed in any of claims 1 to 8 for use in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, Giant cell arteritis or systemic sclerosis.